Phenotypical, Clinical, and Molecular Aspects of Adults and Children With Homozygous Familial Hypercholesterolemia in Iberoamerica.


Journal

Arteriosclerosis, thrombosis, and vascular biology
ISSN: 1524-4636
Titre abrégé: Arterioscler Thromb Vasc Biol
Pays: United States
ID NLM: 9505803

Informations de publication

Date de publication:
10 2020
Historique:
pubmed: 8 8 2020
medline: 25 11 2020
entrez: 8 8 2020
Statut: ppublish

Résumé

Characterize homozygous familial hypercholesterolemia (HoFH) individuals from Iberoamerica. Approach and Results: In a cross-sectional retrospective evaluation 134 individuals with a HoFH phenotype, 71 adults (age 39.3±15.8 years, 38.0% males), and 63 children (age 8.8±4.0 years, 50.8% males) were studied. Genetic characterization was available in 129 (96%). The majority (91%) were true homozygotes (true HoFH, n=79, 43.0% children, 46.8% males) or compound heterozygotes (compound heterozygous familial hypercholesterolemia, n=39, 51.3% children, 46.2% males) with putative pathogenic variants in the There was a high frequency of cardiovascular disease even in children. Phenotype and cardiovascular complications were heterogeneous and associated with the type of molecular defect.

Identifiants

pubmed: 32757650
doi: 10.1161/ATVBAHA.120.313722
doi:

Substances chimiques

APOB protein, human 0
Adaptor Proteins, Signal Transducing 0
Apolipoprotein B-100 0
Biomarkers 0
Cholesterol, LDL 0
LDLR protein, human 0
LDLRAP1 protein, human 0
Receptors, LDL 0
PCSK9 protein, human EC 3.4.21.-
Proprotein Convertase 9 EC 3.4.21.-

Types de publication

Journal Article Multicenter Study Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

2508-2515

Auteurs

Ana Catarina Alves (AC)

Instituto Nacional de Saúde Doutor Ricardo Jorge, Lisboa, Portugal (A.C.A., A.M.M., M.B.).
Departamento de Promoção da Saúde e Prevenção de Doenças Não Transmissíveis, Unidade de I&D, Grupo de Investigação Cardiovascular, Lisboa, Portugal (A.C.A., A.M.M., M.B.).
Faculdade de Ciências, Universidade de Lisboa, BioISI-Biosystems & Integrative Sciences Institute, Portugal (A.C.A., A.M.M., M.B.).

Rodrigo Alonso (R)

Center for Advanced Metabolic Medicine and Nutrition, Santiago, Chile (R. Alonso, A.C.).
Fundación Hipercolesterolemia Familiar, Madrid, Spain (R. Alonso, R. Arroyo, P.M.).

José Luís Diaz-Diaz (JL)

Department of Internal Medicine. Hospital Universitario A Coruña, Spain (J.L.D.-D.).

Ana Margarida Medeiros (AM)

Instituto Nacional de Saúde Doutor Ricardo Jorge, Lisboa, Portugal (A.C.A., A.M.M., M.B.).
Departamento de Promoção da Saúde e Prevenção de Doenças Não Transmissíveis, Unidade de I&D, Grupo de Investigação Cardiovascular, Lisboa, Portugal (A.C.A., A.M.M., M.B.).
Faculdade de Ciências, Universidade de Lisboa, BioISI-Biosystems & Integrative Sciences Institute, Portugal (A.C.A., A.M.M., M.B.).

Cinthia E Jannes (CE)

Heart Institute (InCor) University of São Paulo Medical School Hospital São Paulo, Brazil (C.E.J., A.P.C., J.E.K., R.D.S.).

Alonso Merchan (A)

Fundacion Clinica SHAIO, Cardiologia, Bogota, Colombia (A.M.).

Norma A Vasques-Cardenas (NA)

Universidad Autonoma de Guadalajara, Facultad de Medicina Zapopan, Mexico (N.A.V.-C.).

Ada Cuevas (A)

Center for Advanced Metabolic Medicine and Nutrition, Santiago, Chile (R. Alonso, A.C.).

Ana Paula Chacra (AP)

Heart Institute (InCor) University of São Paulo Medical School Hospital São Paulo, Brazil (C.E.J., A.P.C., J.E.K., R.D.S.).

Jose E Krieger (JE)

Heart Institute (InCor) University of São Paulo Medical School Hospital São Paulo, Brazil (C.E.J., A.P.C., J.E.K., R.D.S.).

Raquel Arroyo (R)

Fundación Hipercolesterolemia Familiar, Madrid, Spain (R. Alonso, R. Arroyo, P.M.).

Francisco Arrieta (F)

Department of Endocrinology, Hospital Ramón y Cajal, Madrid, Spain (F.A.).

Laura Schreier (L)

Facultad de Farmacia y Bioquimica, Universidad de Buenos Aires, Departamento de Bioquímica Clínica, Laboratorio de Lípidos y Aterosclerosis, Argentina (L.S.).

Pablo Corral (P)

Universidad FASTA, Facultad de Medicina, Cátedra Farmacología e Investigación, Mar del Plata, Argentina (P.C.).

Virginia G Bañares (VG)

Administracion Nacional de Laboratorios e Institutos de Salud "Dr Carlos G. Malbrán'', Centro Nacional de Genética Médica, Departamento de Genética Experimental, Buenos Aires, Argentina (V.G.B.).

Maria B Araujo (MB)

Hospital Nacional de Pediatria ¨Dr JP Garraham¨, Servicio de Nutrición, Buenos Aires, Argentina (M.B.A.).

Paula Bustos (P)

Facultad de Farmacia (P.B.), Universidad de Concepción, Chile.

Sylvia Asenjo (S)

Facultad de Medicina (S.A.), Universidad de Concepción, Chile.

Mario Stoll (M)

Comision Honoraria de Salud Cardiovascular, Programa GENYCO, Laboratorio de Genética Molecular, Montevideo, Uruguay (M.S., N.D., X.R., A.R.).

Nicolás Dell'Oca (N)

Comision Honoraria de Salud Cardiovascular, Programa GENYCO, Laboratorio de Genética Molecular, Montevideo, Uruguay (M.S., N.D., X.R., A.R.).

Maria Reyes (M)

Fundación Cardiovascular de Colombia, Cardiologia, Bogotá (R.C.).

Andrés Ressia (A)

Comision Honoraria de Salud Cardiovascular, Programa GENYCO, Laboratorio de Genética Molecular, Montevideo, Uruguay (M.S., N.D., X.R., A.R.).

Rafael Campo (R)

Fundación Cardiovascular de Colombia, Cardiologia, Bogotá (R.C.).

Maria T Magaña-Torres (MT)

Instituto Mexicano del Seguro Social, Centro de Investigación Biomédica del Occidente, Guadalajara, México (M.T.M.-T.).

Roopa Metha (R)

Unidad de Investigación de Enfermedades Metabólicas (R.M., C.A.A.S.).

Carlos A Aguilar-Salinas (CA)

Unidad de Investigación de Enfermedades Metabólicas (R.M., C.A.A.S.).

José J Ceballos-Macias (JJ)

Departamento de Endocrinología y Metabolismo, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, México. Servicio de Endocrinología, Unidad de Especialidades Médicas, Secretaría de la Defensa Nacional, Mexico (J.J.C.-M.).

Álvaro J Ruiz Morales (ÁJR)

Departamento de Medicina Interna, Facultad de Medicina, Pontificia Universidad Javerina, Bogotá, Colombia (A.J.R.).

Pedro Mata (P)

Fundación Hipercolesterolemia Familiar, Madrid, Spain (R. Alonso, R. Arroyo, P.M.).

Mafalda Bourbon (M)

Instituto Nacional de Saúde Doutor Ricardo Jorge, Lisboa, Portugal (A.C.A., A.M.M., M.B.).
Departamento de Promoção da Saúde e Prevenção de Doenças Não Transmissíveis, Unidade de I&D, Grupo de Investigação Cardiovascular, Lisboa, Portugal (A.C.A., A.M.M., M.B.).
Faculdade de Ciências, Universidade de Lisboa, BioISI-Biosystems & Integrative Sciences Institute, Portugal (A.C.A., A.M.M., M.B.).

Raul D Santos (RD)

Heart Institute (InCor) University of São Paulo Medical School Hospital São Paulo, Brazil (C.E.J., A.P.C., J.E.K., R.D.S.).
Hospital Israelita Albert Einstein, Sao Paulo, Brazil (R.D.S.).

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH